Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Nacresertib | Experimental | Participants will receive a single dose of Nacresertib |
|
| Placebo for Nacresertib | Placebo Comparator | Participants will receive a single dose of Placebo for Nacresertib |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nacresertib | Drug | Oral tablet |
| |
| Placebo for Nacresertib |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Nacresertib | Cmax of Nacresertib | Up to 9 Days |
| Time to Cmax (Tmax) of Nacresertib | Tmax of Nacresertib | Up to 9 Days |
| Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of Nacresertib | AUCt of Nacresertib | Up to 9 Days |
| AUC From Time 0 to the Time Infinity (AUCinf) of Nacresertib | AUCinf of Nacresertib | Up to 9 Days |
| Terminal Phase Elimination Rate Constant (Beta) of Nacresertib | Beta of Nacresertib | Up to 9 Days |
| Terminal Phase Elimination Half-Life (t1/2) of Nacresertib | t1/2 of Nacresertib | Up to 9 Days |
| Number of Participants Experiencing Adverse Events (AEs) | Any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment | Up to 42 Days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| ABBVIE CALL CENTER | Contact | 844-663-3742 | abbvieclinicaltrials@abbvie.com |
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CenExel ACT- Anaheim Clinical Trials /ID# 282482 | Anaheim | California | 92801 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Oral tablet |
|